- Home
- OPCH vs PTCT Comparison
OPCH vs PTCT Comparison
Compare OPCH & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPCH
- PTCT
- Stock Information
- Founded
- OPCH N/A
- PTCT 1998
- Country
- OPCH United States
- PTCT United States
- Employees
- OPCH N/A
- PTCT N/A
- Industry
- OPCH Medical/Nursing Services
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- OPCH Health Care
- PTCT Health Care
- Exchange
- OPCH Nasdaq
- PTCT Nasdaq
- Market Cap
- OPCH 4.7B
- PTCT 4.8B
- IPO Year
- OPCH N/A
- PTCT 2013
- Fundamental
- Price
- OPCH $27.04
- PTCT $63.76
- Analyst Decision
- OPCH Buy
- PTCT Buy
- Analyst Count
- OPCH 8
- PTCT 14
- Target Price
- OPCH $35.38
- PTCT $67.00
- AVG Volume (30 Days)
- OPCH 2.0M
- PTCT 1.3M
- Earning Date
- OPCH 10-30-2025
- PTCT 11-06-2025
- Dividend Yield
- OPCH N/A
- PTCT N/A
- EPS Growth
- OPCH 5.29
- PTCT N/A
- EPS
- OPCH 1.26
- PTCT 7.72
- Revenue
- OPCH $5,374,021,000.00
- PTCT $1,764,929,000.00
- Revenue This Year
- OPCH $14.82
- PTCT $119.89
- Revenue Next Year
- OPCH $8.49
- PTCT N/A
- P/E Ratio
- OPCH $21.41
- PTCT $8.28
- Revenue Growth
- OPCH 17.07
- PTCT 96.00
- 52 Week Low
- OPCH $21.39
- PTCT $34.57
- 52 Week High
- OPCH $35.53
- PTCT $67.40
- Technical
- Relative Strength Index (RSI)
- OPCH 41.91
- PTCT 65.90
- Support Level
- OPCH $26.82
- PTCT $57.74
- Resistance Level
- OPCH $28.50
- PTCT $67.40
- Average True Range (ATR)
- OPCH 0.74
- PTCT 2.31
- MACD
- OPCH -0.02
- PTCT 0.16
- Stochastic Oscillator
- OPCH 18.14
- PTCT 61.28
About OPCH Option Care Health Inc.
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders among others.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.